This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rigter, I. M.
Right arrow Articles by Guchelaar, H.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rigter, I. M.
Right arrow Articles by Guchelaar, H.-J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2004, p. 1051-1054, Vol. 48, No. 3
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.3.1051-1054.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Relative Bioavailability of Three Newly Developed Albendazole Formulations: a Randomized Crossover Study with Healthy Volunteers

I. M. Rigter,1 H. G. Schipper,2 R. P. Koopmans,3 H. J. M. van Kan,1 H. W. Frijlink,4 P. A. Kager,2 and H.-J. Guchelaar1*

Department of Clinical Pharmacy,1 Department of Internal Medicine,3 Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, Amsterdam,2 Department of Pharmacy, Division of Pharmaceutical Technology, University of Groningen, Groningen, The Netherlands4

Received 22 October 2003/ Returned for modification 13 November 2003/ Accepted 1 December 2003

This study of healthy volunteers shows that the relative bioavailability of albendazole formulations that use arachis oil-polysorbate 80 or hydroxypropyl-ß-cyclodextrin as an excipient was enhanced 4.3- and 9.7-fold compared to the results seen with commercial tablets. Administration of macrogol suppositories did not result in measurable plasma concentrations of albendazole sulfoxide.

* Corresponding author. Present address: Leiden University Medical Center, Clinical Pharmacy & Toxicology, P.O. Box 9600, 2300 RC Leiden, The Netherlands. Phone: 31 70 526 2790. Fax: 011 31 71 524 8101. E-mail: h.j.guchelaar{at}lumc.nl.

Antimicrobial Agents and Chemotherapy, March 2004, p. 1051-1054, Vol. 48, No. 3
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.3.1051-1054.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»